Filing Flows › Prelude Therapeutics (PRLD) › Q4 2025
Prelude Therapeutics (PRLD) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 10, 2026
Prelude Therapeutics (PRLD) reported revenue of $5.6M for the fourth quarter 2025 (Q4 2025), +41% from a year earlier and -13% from the quarter before. Operating margin was -307.6%, net loss $16.5M (291.8% of revenue).
Prelude Therapeutics, Q4 2025: revenue $5.6M (+41% year over year), operating margin -307.6%, net loss $16.5M, operating cash flow $23.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.6M | -13% | +41% |
| Operating profit | −$17.3M | — | — |
| Net earnings | −$16.5M | — | — |
| Operating cash flow | $23.1M | — | — |
What changed
Revenue was $5.6M in Q4 2025, up 41% year over year and down 13% from the previous quarter.
Operating costs exceeded revenue by $17.3M, an operating margin of -307.6%. Total costs fell 39% while revenue rose 41%. The quarter ended with a net loss of $16.5M, narrower than the previous quarter's $19.7M loss.
Operating cash flow was $23.1M. Non-cash charges added back $418K of depreciation and amortization and $1.8M of share-based compensation. Working capital and other items added $37.3M.
Questions
What was Prelude Therapeutics' revenue in the fourth quarter 2025?
Prelude Therapeutics (PRLD) reported revenue of $5.6M for the fourth quarter 2025 (Q4 2025), +41% from a year earlier and -13% from the quarter before.
Was Prelude Therapeutics profitable in the fourth quarter 2025?
Operating loss was $17.3M (-307.6% of revenue) and net loss $16.5M.